drugset / Trial / NCT06248099
Nebivolol Tablets 5 mg Relative to Nebilet Tablets 5 mg
RandomizedCrossoverOpen-labelBasic science
Summary
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 28 days washout period between the doses.
Timeline
- Start
- 2024-07-09
- Primary completion
- 2024-08-17
- Completion
- 2024-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nebivolol | Other / unclassified | 5 mg | Oral |
Indications
No indication recorded.